PT - JOURNAL ARTICLE AU - XIANG-JUN TANG AU - JUN-TI LU AU - HAN-JUN TU AU - KUAN-MING HUANG AU - RUI FU AU - GANG CAO AU - MIN HUANG AU - LONG-HAI CHENG AU - LONG-JUN DAI AU - LI ZHANG TI - TRAIL-engineered Bone Marrow-derived Mesenchymal Stem Cells: TRAIL Expression and Cytotoxic Effects on C6 Glioma Cells DP - 2014 Feb 01 TA - Anticancer Research PG - 729--734 VI - 34 IP - 2 4099 - http://ar.iiarjournals.org/content/34/2/729.short 4100 - http://ar.iiarjournals.org/content/34/2/729.full SO - Anticancer Res2014 Feb 01; 34 AB - Background: TNF-related apoptosis-inducing ligand (TRAIL) is considered as a tumor cell-specific cytotoxic agent. Through the aid of mesenchymal stem cells (MSCs), TRAIL is capable of inducing apoptosis of tumor cells in tumor sites. The present study was performed to investigate the cytotoxic effects of TRAIL-engineered MSCs on glioblastoma cells (C6) in vitro. Materials and Methods: An expression vector of secreting form of TRAIL was used to engineer MSCs. The cytotoxic effects of TRAIL-transfected MSCs on C6 cells were invstigated using the MTT method and Hochest33258 staining after co-culture of the two cell types. Results: TRAIL and control plasmid transfection of MSCs showed no significant effect on MSC's viability (p>0.05). A significant inhibition of C6 cells was observed when they were co-cultured with TRAIL-engineered MSCs (63.7%±0.12, p<0.05). Conclusion: Mesenchymal stem cells were very well tolerant to the transfection of TRAIL-bearing vectors. The cytotoxic effects of TRAIL-engineered MSCs on C6 cells indicates the therapeutic potential of this strategy for treatment of glioblastoma patients.